These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 31955148

  • 1. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
    Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, Rebersek M.
    Radiol Oncol; 2020 Jan 19; 54(1):119-127. PubMed ID: 31955148
    [Abstract] [Full Text] [Related]

  • 2. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
    Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.
    Ann Oncol; 2019 Apr 01; 30(4):582-588. PubMed ID: 30715153
    [Abstract] [Full Text] [Related]

  • 3. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW.
    J Immunother; 2018 Apr 01; 41(2):86-95. PubMed ID: 29252916
    [Abstract] [Full Text] [Related]

  • 4. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.
    JAMA; 2016 Apr 19; 315(15):1600-9. PubMed ID: 27092830
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
    Li T, Jia DD, Teng LS.
    Invest New Drugs; 2020 Oct 19; 38(5):1334-1341. PubMed ID: 32072356
    [Abstract] [Full Text] [Related]

  • 6. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
    Liu FX, Ou W, Diede SJ, Whitman ED.
    Medicine (Baltimore); 2019 Jul 19; 98(30):e16542. PubMed ID: 31348273
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
    Yokota K, Takenouchi T, Fujisawa Y, Fukushima S, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Han S, Watanabe M, Noguchi K, Yamazaki N.
    J Dermatol; 2024 May 19; 51(5):632-642. PubMed ID: 38529706
    [Abstract] [Full Text] [Related]

  • 8. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 19; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 9. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
    Durot C, Mulé S, Soyer P, Marchal A, Grange F, Hoeffel C.
    Eur Radiol; 2019 Jun 19; 29(6):3183-3191. PubMed ID: 30645669
    [Abstract] [Full Text] [Related]

  • 10. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
    Mesti T, Ceplak Mencin V, Mileva Boshkoska B, Ocvirk J.
    Radiol Oncol; 2021 May 04; 55(3):354-361. PubMed ID: 33939899
    [Abstract] [Full Text] [Related]

  • 11. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Cimminiello C, Indini A, Di Guardo L, Prisciandaro M, Randon G, Tolomio E, De Braud F, Del Vecchio M.
    Melanoma Res; 2019 Jun 04; 29(3):289-294. PubMed ID: 30520799
    [Abstract] [Full Text] [Related]

  • 12. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.
    Eur J Cancer; 2018 Sep 04; 101():236-243. PubMed ID: 30096704
    [Abstract] [Full Text] [Related]

  • 13. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.
    Lancet; 2017 Oct 21; 390(10105):1853-1862. PubMed ID: 28822576
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN.
    Cancer Med; 2021 Apr 21; 10(7):2293-2299. PubMed ID: 33686688
    [Abstract] [Full Text] [Related]

  • 15. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
    McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.
    Lancet Oncol; 2018 Mar 21; 19(3):310-322. PubMed ID: 29449192
    [Abstract] [Full Text] [Related]

  • 16. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
    Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, Petrone G, Rindi G, Zollino M, Blasi MA, Cassano A, Bria E, Tortora G, Schinzari G.
    Cancer Immunol Immunother; 2019 Jul 21; 68(7):1179-1185. PubMed ID: 31175402
    [Abstract] [Full Text] [Related]

  • 17. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
    Cowey CL, Scherrer E, Boyd M, Aguilar KM, Beeks A, Krepler C.
    J Immunother; 2019 Jul 21; 44(6):224-233. PubMed ID: 33734142
    [Abstract] [Full Text] [Related]

  • 18. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 21; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 19. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA, Althouse S, Meyer Z, Hanna N, Durm G.
    Clin Lung Cancer; 2021 Jul 21; 22(4):274-281. PubMed ID: 33610454
    [Abstract] [Full Text] [Related]

  • 20. Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers.
    Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, van der Westhuizen A.
    Pharmacol Res Perspect; 2021 Aug 21; 9(4):e00808. PubMed ID: 34129290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.